Literature DB >> 26719354

Blocking α5β1 Integrin Attenuates sCD40L-Mediated Platelet Activation.

Damir Simic1, Nancy Bogdan1, Fang Teng2, Monicah Otieno1.   

Abstract

The soluble form of CD40L (sCD40L) is a platelet-derived mediator that links inflammation, hemostasis, and vascular dysfunction. Indeed, blockade of CD40L by neutralizing antibodies or genetic disruption in mice prevents atherosclerosis and atherothrombosis. Until recently, it was believed that CD40 and αIIbβ3 were the only receptors on platelets responsible for binding sCD40L, leading to platelet activation and initiation of thrombotic events. Recent findings showed α5β1 integrin as a novel platelet sCD40L receptor, with an unknown function. For the first time, using anti-α5β1 blocking antibodies, we show that sCD40L/α5β1 interaction leads to platelet activation as evaluated in the human whole blood. Establishing α5β1 integrin's role in platelet activation, and therefore thrombosis will help further shed light on the etiology of thrombotic disease.

Entities:  

Keywords:  CD40 ligand; and flow cytometry; platelet activation; α5β1 integrin

Mesh:

Substances:

Year:  2015        PMID: 26719354     DOI: 10.1177/1076029615624549

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  5 in total

Review 1.  Integrin signaling in atherosclerosis.

Authors:  Alexandra C Finney; Karen Y Stokes; Christopher B Pattillo; A Wayne Orr
Journal:  Cell Mol Life Sci       Date:  2017-02-28       Impact factor: 9.261

Review 2.  Novel Functions of Integrins as Receptors of CD154: Their Role in Inflammation and Apoptosis.

Authors:  Ghada S Hassan; Suzanne Salti; Walid Mourad
Journal:  Cells       Date:  2022-05-25       Impact factor: 7.666

3.  CD40L Priming of Platelets via NF-κB Activation is CD40- and TAK1-Dependent.

Authors:  Kevin Kojok; Souhad El Akoum; Mira Mohsen; Walid Mourad; Yahye Merhi
Journal:  J Am Heart Assoc       Date:  2018-12-04       Impact factor: 5.501

Review 4.  CD40L and Its Receptors in Atherothrombosis-An Update.

Authors:  Nathaly Anto Michel; Andreas Zirlik; Dennis Wolf
Journal:  Front Cardiovasc Med       Date:  2017-06-20

Review 5.  The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease.

Authors:  Laura A Bosmans; Lena Bosch; Pascal J H Kusters; Esther Lutgens; Tom T P Seijkens
Journal:  J Cardiovasc Transl Res       Date:  2020-03-28       Impact factor: 4.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.